The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hepatorenal Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hepatorenal Syndrome


High impact information on Hepatorenal Syndrome


Chemical compound and disease context of Hepatorenal Syndrome


Biological context of Hepatorenal Syndrome


Gene context of Hepatorenal Syndrome


Analytical, diagnostic and therapeutic context of Hepatorenal Syndrome


  1. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Zipser, R.D., Radvan, G.H., Kronborg, I.J., Duke, R., Little, T.E. Gastroenterology (1983) [Pubmed]
  2. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Moore, K., Ward, P.S., Taylor, G.W., Williams, R. Gastroenterology (1991) [Pubmed]
  3. Circulatory function and hepatorenal syndrome in cirrhosis. Ruiz-del-Arbol, L., Monescillo, A., Arocena, C., Valer, P., Ginès, P., Moreira, V., Milicua, J.M., Jiménez, W., Arroyo, V. Hepatology (2005) [Pubmed]
  4. Renal blood flow detection with Doppler ultrasonography in patients with hepatic cirrhosis. Celebi, H., Dönder, E., Celiker, H. Arch. Intern. Med. (1997) [Pubmed]
  5. Plasma endothelin and the hepatorenal syndrome. Agarwal, R. N. Engl. J. Med. (1993) [Pubmed]
  6. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. Moore, K., Wendon, J., Frazer, M., Karani, J., Williams, R., Badr, K. N. Engl. J. Med. (1992) [Pubmed]
  7. Dopamine in the hepatorenal syndrome. Wilson, J.R. JAMA (1977) [Pubmed]
  8. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome? Sen, S., Mookerjee, R.P., Jalan, R. Gastroenterology (2002) [Pubmed]
  9. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Ginès, A., Escorsell, A., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V. Gastroenterology (1993) [Pubmed]
  10. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Zipser, R.D., Kronborg, I., Rector, W., Reynolds, T., Daskalopoulos, G. Gastroenterology (1984) [Pubmed]
  11. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Holt, S., Goodier, D., Marley, R., Patch, D., Burroughs, A., Fernando, B., Harry, D., Moore, K. Lancet (1999) [Pubmed]
  12. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Guevara, M., Ginès, P., Fernández-Esparrach, G., Sort, P., Salmerón, J.M., Jiménez, W., Arroyo, V., Rodés, J. Hepatology (1998) [Pubmed]
  13. Circadian rhythm of arginine vasopressin in hepatorenal syndrome. Pasqualetti, P., Festuccia, V., Collacciani, A., Acitelli, P., Casale, R. Nephron (1998) [Pubmed]
  14. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Demirtaş, S., Bozbaş, A., Akbay, A., Yavuz, Y., Karaca, L. Clin. Chim. Acta (2001) [Pubmed]
  15. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Ganne-Carrié, N., Hadengue, A., Mathurin, P., Durand, F., Erlinger, S., Benhamou, J.P. Dig. Dis. Sci. (1996) [Pubmed]
  16. Dopamine-frusemide therapy in acute renal failure. Graziani, G., Casati, S., Cantaluppi, A., Citterio, A., Aroldi, A., Scalamogna, A., Brancaccio, D., Ponticelli, C. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association. (1983) [Pubmed]
  17. Treatment of hepatorenal syndrome: lessons from the MARS trial. Mullen, K.D. Hepatology (2002) [Pubmed]
  18. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Govindarajan, S., Nast, C.C., Smith, W.L., Koyle, M.A., Daskalopoulos, G., Zipser, R.D. Hepatology (1987) [Pubmed]
  19. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Maier, K.G., Roman, R.J. Curr. Opin. Nephrol. Hypertens. (2001) [Pubmed]
  20. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release. Fukunaga, M., Yura, T., Badr, K.F. J. Cardiovasc. Pharmacol. (1995) [Pubmed]
  21. Tubular dysfunction in the deeply jaundiced patient with hepatorenal syndrome. Rector, W.G., Kanel, G.C., Rakela, J., Reynolds, T.B. Hepatology (1985) [Pubmed]
  22. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Gülberg, V., Bilzer, M., Gerbes, A.L. Hepatology (1999) [Pubmed]
  23. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. Fevery, J., Van Cutsem, E., Nevens, F., Van Steenbergen, W., Verberckmoes, R., De Groote, J. J. Hepatol. (1990) [Pubmed]
  24. Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Schroeder, E.T., Anderson, G.H., Smulyan, H. Kidney Int. (1979) [Pubmed]
  25. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. Moore, K.P., Taylor, G.W., Maltby, N.H., Siegers, D., Fuller, R.W., Dollery, C.T., Williams, R. J. Hepatol. (1990) [Pubmed]
WikiGenes - Universities